文献速递认知障碍与痴呆

开发多臂多阶段临床试验中多发性硬化的 interim 结局指标

Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis.
PubMed 文献 · Neurology · 2026-09-24

该研究基于3项进展型多发性硬化(PMS)试验的纵向数据,评估患者报告结局指标(PROMs)能否作为多臂多阶段(MAMS)试验的 interim 结局。结果显示MSIS-29v2 PH、MSWS-12v2及其复合评分与6个月确认的EDSS残疾进展显著相关,复合评分在12个月时可检测治疗效应且样本量可行。

要点

  • MSIS-29v2 PH、MSWS-12v2及复合评分与36个月内6个月确认的EDSS残疾进展相关。
  • 复合评分在12个月时可检测50%治疗效应,每组125例时把握度≥90%。
  • 这些PROMs适合作为PMS的MAMS试验 interim 结局指标。

核心结论

  • MSIS-29v2 PH、MSWS-12v2及复合评分的变化与6个月确认的EDSS残疾进展相关,复合评分在12个月时具有足够统计把握度检测治疗效应。

研究设计与样本

  • pooled analysis of 11,052 longitudinal visits from 3 PMS trials,分析1,927名参与者(平均年龄54岁,SD 7.2,66%女性)。

主要发现

  • EDSS 6个月确认残疾进展风险与12个月评分每增加1个标准差显著相关:MSIS-29v2 PH(HR 1.20 [1.08-1.33])、MSWS-12v2(HR 1.26 [1.13-1.40])、复合评分(HR 1.29 [1.16-1.44];所有p < 0.0001)。
  • 模拟显示复合评分每组125例可检测50%治疗效应对12个月平均变化的把握度≥90%,每组200例把握度≥95%。

关键数值与推荐

  • MSIS-29v2 PH每增加1个标准差,EDSS 6个月确认残疾进展的HR为1.20(95%CI 1.08-1.33)。
  • MSWS-12v2每增加1个标准差,EDSS 6个月确认残疾进展的HR为1.26(95%CI 1.13-1.40)。
  • 复合评分每增加1个标准差,EDSS 6个月确认残疾进展的HR为1.29(95%CI 1.16-1.44)。

临床怎么用

  • 在PMS的MAMS试验中,可考虑使用MSIS-29v2 PH、MSWS-12v2或复合评分作为 interim 结局指标。
  • 复合评分在12个月时可检测治疗效应,所需样本量每组125例(把握度≥90%)。

局限性

  • 研究基于3项PMS试验的汇总分析,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Multi-arm multistage (MAMS) clinical trials use interim outcome stage analyses to test multiple candidate treatments, determining which should proceed to the next trial stage. The reduced time, cost, and participant numbers, compared with current separated phases 2 and 3 clinical trials, could expedite the development of treatments in neurodegenerative diseases, such as progressive multiple sclerosis (PMS). MAMS trial interim outcomes must reflect the final stage outcome and be able to detect treatment effects with high power at interim stages. Patient-reported outcomes (PROMs) are cost-effective and highly accessible, making them promising MAMS trial interim outcome measures. We determined whether the MS Quality of Life 54 Physical Health Composite, MS Impact Scale 29 version 2 physical health subscore (MSIS-29v2 PH), MS Walking Scale 12 version 2 (MSWS-12v2), or their composite could act as interim outcome measures in MAMS PMS trials. METHODS: Using a pooled analysis of 11,052 longitudinal visits from 3 PMS trials, we assessed the relationship of PROM change at early time points with 6-month confirmed disability progression (CDP) in the Expanded Disability Status Scale (EDSS) up to 36 months through Cox proportional hazards. To minimize PROM ceiling effects, we generated an MSIS-29v2 PH and MSWS-12v2 composite, prioritizing greatest change. We calculated the required sample size when these PROMs were used as interim measures. RESULTS: We analyzed 1,927 of the 2,046 available participants (mean age 54 [SD 7.2] years and 66% female). EDSS 6-month CDP risk was significantly associated with each 1-standard deviation 12-month score increase for the MSIS-29v2 PH (hazard ratio [HR] 1.20 [1.08-1.33]), MSWS-12v2 (HR 1.26 [1.13-1.40]), and composite (HR 1.29 [1.16-1.44]; all p < 0.0001). In simulations, using the composite, n = 125/arm can detect a 50% treatment effect on mean 12-month change with power ≥90% and 200/arm with a power ≥95%. DISCUSSION: Changes in the MSIS-29v2 PH, MSWS-12v2, and composite scores associated with ≥6-month EDSS CDP up to 36 months. The composite has sufficient statistical power to detect treatment effects at 12 months. These PROMs are well placed to play a role in interim analysis in MAMS trials in PMS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Apap Mangion S, Wade C, Coles D, et al. Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis. Neurology. 2026. PMID: 42784778. doi:10.1212/WNL.0000000000218426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。